Open1.510 | Close1.580 |
Vol / Avg.2.159M / 3.844M | Mkt Cap180.811M |
Day Range1.500 - 1.600 | 52 Wk Range0.700 - 8.850 |
Esperion Therapeutics Stock (NASDAQ: ESPR) stock price, news, charts, stock research, profile.
Open1.510 | Close1.580 |
Vol / Avg.2.159M / 3.844M | Mkt Cap180.811M |
Day Range1.500 - 1.600 | 52 Wk Range0.700 - 8.850 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.430 | -0.370 | 0.0600 | ||||
REV | 29.580M | 33.969M | 4.389M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-11-20 | JP Morgan | Jessica Fye | Reinstates | Neutral | - | - | - |
2023-11-13 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-11-07 | Needham | Serge Belanger | Maintains | BuyBuy | Lowers | 9.00 | 8.00 |
2023-10-02 | Needham | Serge Belanger | Reiterates | BuyBuy | Maintains | - | 9.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ESPR | Esperion Therapeutics | 6% | 180.8M |
AVIR | Atea Pharmaceuticals | -1.34% | 245.3M |
ZVRA | Zevra Therapeutics | 3.84% | 201.4M |
XERS | Xeris Biopharma Holdings | 1.04% | 268M |
LBPH | Longboard Pharmaceuticals | 0% | 113.3M |
You can purchase shares of Esperion Therapeutics (NASDAQ: ESPR) through any online brokerage.
Other companies in Esperion Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Zevra Therapeutics (NASDAQ:ZVRA), Xeris Biopharma Holdings (NASDAQ:XERS), Longboard Pharmaceuticals (NASDAQ:LBPH) and Ocular Therapeutix (NASDAQ:OCUL).
The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by JP Morgan on Monday, November 20, 2023. The analyst firm set a price target for 0.00 expecting ESPR to fall to within 12 months (a possible -100.00% downside). 24 analyst firms have reported ratings in the last year.
The stock price for Esperion Therapeutics (NASDAQ: ESPR) is $1.59 last updated December 7, 2023 at 10:06 PM UTC.
There is no dividend information for Esperion Therapeutics.
Esperion Therapeutics’s Q4 earnings are confirmed for Tuesday, February 20, 2024.
There is no upcoming split for Esperion Therapeutics.
Esperion Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.